Hims & Hers Health, Inc.

HIMS

NYSE; healthcare; SIC 8011, Services-Offices & Clinics of Doctors of Medicine; CIK 0001773751

A

strongest fifth of 370 graded peers in healthcare

rank 30 of 370; percentile 7.9; sampling error 2.5 points; lower is stronger

A B C D E

A, the bull




Scoreboard	
Profitability	B percentile 31.9
Solvency	C percentile 51.8
Growth and financing	A percentile 6.3
Reliability	0.91 AUC filers with $591M to $2.67B assets; 95% interval 0.88 to 0.94; 160 events, 2020 to 2025
Peer failure rate	1.01% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025
Size band	$591M to $2.67B assets total assets $2.2B
Standard universe	inside revenue above $1M and assets above $10M
Warnings	none triggered not computable: dilution, distress, fortress balance sheet
Inputs computable	7 of 14
Graded from	filings received through Feb 23, 2026 249 days before the rescan; latest periodic filing 10-Q received Aug 10, 2026
Last close	$29.70 2026-10-29; market equity $0; no price enters the letter

Share price, twelve months to the rescan



Split-adjusted close. Each lollipop is a rescan and carries the letter held then.

Letter at every rescan, 2012 to 2026



Sector percentile at each rescan, stronger toward the top; facts filed by each date only.

Business, in the company's words

opening of Item 1 of the 10-K received Feb 23, 2026

Launched in 2017, Hims & Hers Health, Inc. (and together with its subsidiaries, "Hims & Hers", the "Company", "we", "us" or "our") has built a consumer-first platform transforming the way customers fulfill their health and wellness needs. We believe that the Company has the technical infrastructure, distributed provider network, and access to clinical capabilities to lead the migration of routine office visits to a personalized, digital, accessible format.

The fourteen inputs

lower percentile is stronger; sleeves and inputs within a sleeve carry equal weight


Input	Value	Peer median	Percentile, 0 to 100	Pct	Peers	Period end
Profitability, sleeve percentile 31.9						
Gross profitability	80.4%	32.3%		7.9	369	2025-12-31
Return on invested capital	not computable	9.3%				
one or more required annual facts are missing						
Accruals ratio	(12.0%)	(6.6%)		36.1	805	2025-12-31

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Gross margin stability, five years	2.9 pts	2.8 pts	51.9	242	2025-12-31
Solvency, sleeve percentile 51.8					
Twelve-month failure probability	not computable	0.07%			
liabilities and a nearby cover-page share count are required at 2026-06-30					
Altman Z double-prime	1.61	(0.33)	30.5	751	2025-12-31
Net debt to EBITDA	not computable	1.82x			
one or more required annual facts are missing					
Interest coverage	not computable	(4.51x)			
interest expense must exceed $100,000					
Current ratio	1.90x	2.94x	73.0	832	2025-12-31
Growth and financing, sleeve percentile 6.3					
Revenue growth, three-year compound	64.5%	10.1%	9.2	413	2025-12-31
Free cash flow growth, three-year compound	not computable	10.9%			
four consecutive annual FCF observations are required; found 2					
Reinvestment rate	not computable	37.1%			
pretax income must exceed the validity floor and imply a 0%-100% tax rate					
Asset growth, three years	80.5%	2.1%	3.3	697	2025-12-31
Net share issuance, one year	not computable	2.5%			
two annual share counts are required; found 0					

Among 370 peers

healthcare; letters are fifths of this list



Composite score of every graded peer, smoothed; vertical rules are the letter band edges; stronger to the left.

Rank	Company	Percentile	Letter	Warnings
25	AtriCure, Inc. (ATRC)	6.5	A	
26	Crispr Therapeutics AG (CRSP)	6.8	A	
27	United Therapeutics Corp. (UTHR)	7.0	A	
28	iRhythm Holdings, Inc. (IRTC)	7.3	A	fortress balance sheet
29	Globus Medical Inc. (GMED)	7.6	A	
30	Hims & Hers Health, Inc. (HIMS)	7.9	A	
31	Alkermes plc. (ALKS)	8.1	A	
32	Veracyte, Inc. (VCYT)	8.4	A	
33	Gyre Therapeutics, Inc. (GYRE)	8.7	A	fortress balance sheet
34	Si-Bone, Inc. (SIBN)	8.9	A	fortress balance sheet
35	Xtant Medical Holdings, Inc. (XTNT)	9.2	A	fortress balance sheet

What the price implies

at the 2026-10-29 close; none of these enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(47.8%)	7.7%	15
Distance from 52-week high	(36.4%)	(26.6%)	37
EBIT to enterprise value	not computable	(1.4%)	
Free cash flow yield	not computable	(0.9%)	

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

Book value to price	not computable	0.27	
Sales to price	not computable	0.30	
Composite equity issuance, five years	not computable	20.5%	
Relative strength against the sector, log excess return	(0.86)	(0.14)	15

Diagnostics

shown on every report; none enters the grade

Measure	Value
Piotroski F-score None of 9, period end 2025-12-31	
Return on assets above zero	pass
Operating cash flow above zero	pass
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	pass
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	$609.8M
Operating cash flow, four quarters	$263.4M
Months of runway	not finite
Days since last periodic filing	81 (10-Q received Aug 10, 2026)
Median daily dollar volume, 63 sessions	$272.4M

Sources

every fact behind the inputs; each row links to its filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	gross profit	us-gaap:GrossProfit	$1.7B	2025-12-31	2026-02-23	10-K	26-000022
2	assets	us-gaap:Assets	$2.2B	2025-12-31	2026-02-23	10-K	26-000022
3	net income	us-gaap:NetIncomeLoss	$128.4M	2025-12-31	2026-02-23	10-K	26-000022
4	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	$300.0M	2025-12-31	2026-02-23	10-K	26-000022
5	assets	us-gaap:Assets	$707.5M	2024-12-31	2026-02-23	10-K	26-000022
6	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$2.3B	2025-12-31	2026-02-23	10-K	26-000022
7	gross profit	us-gaap:GrossProfit	$1.2B	2024-12-31	2026-02-23	10-K	26-000022
8	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$1.5B	2024-12-31	2026-02-23	10-K	26-000022
9	gross profit	us-gaap:GrossProfit	$714.9M	2023-12-31	2026-02-23	10-K	26-000022
10	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$872.0M	2023-12-31	2026-02-23	10-K	26-000022
11	gross profit	us-gaap:GrossProfit	$408.7M	2022-12-31	2025-02-24	10-K	25-000062
12	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$526.9M	2022-12-31	2025-02-24	10-K	25-000062
13	gross profit	us-gaap:GrossProfit	$204.5M	2021-12-31	2024-02-26	10-K	24-000025
14	revenue	us-gaap:RevenueFromContractWithCustomerExcludingA...	$271.9M	2021-12-31	2024-02-26	10-K	24-000025
15	current assets	us-gaap:AssetsCurrent	$767.6M	2025-12-31	2026-02-23	10-K	26-000022
16	current liabilities	us-gaap:LiabilitiesCurrent	$404.4M	2025-12-31	2026-02-23	10-K	26-000022
17	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-$113.8M	2025-12-31	2026-02-23	10-K	26-000022
18	operating income	us-gaap:OperatingIncomeLoss	$105.6M	2025-12-31	2026-02-23	10-K	26-000022
19	book equity	us-gaap:StockholdersEquity	$540.9M	2025-12-31	2026-02-23	10-K	26-000022
20	liabilities	us-gaap:Liabilities	$1.6B	2025-12-31	2026-02-23	10-K	26-000022
21	operating income	us-gaap:OperatingIncomeLoss	-$115.0M	2021-12-31	2024-02-26	10-K	24-000025
22	interest expense	us-gaap:InterestExpense	$0	2021-12-31	2022-02-24	10-K	22-000039
23	capital expenditure	us-gaap:PaymentsToAcquireProductiveAssets	$242.6M	2025-12-31	2026-02-23	10-K	26-000022
24	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	$54.5M	2025-12-31	2026-02-23	10-K	26-000022
25	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeInc...	$123.9M	2025-12-31	2026-02-23	10-K	26-000022
26	income tax	us-gaap:IncomeTaxExpenseBenefit	-$4.4M	2025-12-31	2026-02-23	10-K	26-000022

Not investment advice. Informational and educational only. Data from SEC EDGAR, may contain errors, is not warranted. The grade ranks reported financial condition and is not a return forecast.

27	current assets	us-gaap:AssetsCurrent	$395.8M	2024-12-31	2026-02-23	10-K	26-000022
28	current liabilities	us-gaap:LiabilitiesCurrent	$221.4M	2024-12-31	2026-02-23	10-K	26-000022
29	assets	us-gaap:Assets	$441.2M	2023-12-31	2025-02-24	10-K	25-000062
30	assets	us-gaap:Assets	$366.3M	2022-12-31	2024-02-26	10-K	24-000025